Cilostazol and isosorbide mononitrate for the prevention of progression of cerebral small vessel disease: Baseline data and statistical analysis plan for the Lacunar Intervention Trial-2 (LACI-2) (ISRCTN14911850)
View ORCID ProfilePhilip M Bath, Iris Mhlanga, View ORCID ProfileLisa J Woodhouse, View ORCID ProfileFergus Doubal, View ORCID ProfileKatherine Oatey, View ORCID ProfileAlan A Montgomery, View ORCID ProfileJoanna M Wardlaw, the LACI-2 Investigators
doi: https://doi.org/10.1101/2022.05.31.22275743
Philip M Bath
1Stroke Trials Unit, Mental Health & Clinical Neuroscience, University of Nottingham, Nottingham UK
2Stroke, Nottingham University Hospitals NHS Trust, Nottingham UK
Iris Mhlanga
1Stroke Trials Unit, Mental Health & Clinical Neuroscience, University of Nottingham, Nottingham UK
Lisa J Woodhouse
1Stroke Trials Unit, Mental Health & Clinical Neuroscience, University of Nottingham, Nottingham UK
Fergus Doubal
3Neuroimaging Sciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh UK
4Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh UK
Katherine Oatey
4Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh UK
Alan A Montgomery
5Nottingham Clinical Trials Unit, University of Nottingham, Nottingham UK
Joanna M Wardlaw
3Neuroimaging Sciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh UK
6UK Dementia Research Institute at the University of Edinburgh
Article usage
Posted June 21, 2022.
Cilostazol and isosorbide mononitrate for the prevention of progression of cerebral small vessel disease: Baseline data and statistical analysis plan for the Lacunar Intervention Trial-2 (LACI-2) (ISRCTN14911850)
Philip M Bath, Iris Mhlanga, Lisa J Woodhouse, Fergus Doubal, Katherine Oatey, Alan A Montgomery, Joanna M Wardlaw, the LACI-2 Investigators
medRxiv 2022.05.31.22275743; doi: https://doi.org/10.1101/2022.05.31.22275743
Cilostazol and isosorbide mononitrate for the prevention of progression of cerebral small vessel disease: Baseline data and statistical analysis plan for the Lacunar Intervention Trial-2 (LACI-2) (ISRCTN14911850)
Philip M Bath, Iris Mhlanga, Lisa J Woodhouse, Fergus Doubal, Katherine Oatey, Alan A Montgomery, Joanna M Wardlaw, the LACI-2 Investigators
medRxiv 2022.05.31.22275743; doi: https://doi.org/10.1101/2022.05.31.22275743
Subject Area
Subject Areas
- Addiction Medicine (319)
- Allergy and Immunology (621)
- Anesthesia (162)
- Cardiovascular Medicine (2331)
- Dermatology (205)
- Emergency Medicine (373)
- Epidemiology (11680)
- Forensic Medicine (10)
- Gastroenterology (690)
- Genetic and Genomic Medicine (3667)
- Geriatric Medicine (344)
- Health Economics (629)
- Health Informatics (2355)
- Health Policy (923)
- Hematology (339)
- HIV/AIDS (768)
- Medical Education (363)
- Medical Ethics (104)
- Nephrology (395)
- Neurology (3423)
- Nursing (193)
- Nutrition (515)
- Oncology (1796)
- Ophthalmology (530)
- Orthopedics (213)
- Otolaryngology (284)
- Pain Medicine (229)
- Palliative Medicine (66)
- Pathology (444)
- Pediatrics (1018)
- Primary Care Research (413)
- Public and Global Health (6072)
- Radiology and Imaging (1249)
- Respiratory Medicine (818)
- Rheumatology (375)
- Sports Medicine (320)
- Surgery (396)
- Toxicology (50)
- Transplantation (171)
- Urology (144)